Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Multiple Myeloma 10Leukemia, Myeloid, Acute 4Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Waldenstrom Macroglobulinemia 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Neoplasms 1Myeloproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Gliosarcoma 1Glioblastoma 1Endometrial Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Cyclophosphamide 12fludarabine 11fludarabine phosphate 8Tacrolimus 8Melphalan 8Whole-Body Irradiation 7Mycophenolic Acid 7Thiotepa 6Imatinib Mesylate 6nilotinib 5Granulocyte Colony-Stimulating Factor 5Dasatinib 5Busulfan 5venetoclax 4ponatinib 4asciminib 4Mesna 4bosutinib 3Sirolimus 3Peripheral Blood Stem Cell Transplantation 3thymoglobulin 2ruxolitinib 2blinatumomab 2Patient Reported Outcome Measures 2Filgrastim 2Antilymphocyte Serum 2selinexor 1plerixafor 1Triamcinolone 1Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × selinexor × Clear all
NCT02091245 2026-05-29

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
16 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡